Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06612788 · ClinicalTrials.gov registry record · NA
Exablate for LIFU Neuromodulation in Patients With Opioid Use Disorder (OUD)
A NA study, sponsored by West Virginia University.
- Completed
- Registry status
- NA
- Development phase
- 5
- Enrollment target
NCT06612788: Completed NA study, sponsored by West Virginia University.
NCT06612788 is a NA study that has completed, run by West Virginia University. The registered enrollment target is 5 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06612788, a NA study, has completed, sponsored by West Virginia University.
- COMPLETED
- Registry status
- NA
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this clinical trial is to investigate Low Intensity Focused Ultrasound (LIFU) using the Exablate® Model 4000 Type 2.0/2.1 as an adjunctive neuromodulatory treatment for OUD (Opioid Use Disorder) by assessing its safety and tolerability in subjects with OUD.
Primary Outcome
Safety will be assessed by recording all adverse events that are treatment related. Each Adverse Event will be documented for patterns of occurence.
Interventions
- DEVICE Exablate Model 4000 Type 2.0/2.1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2023-09-19 |
| Est. Completion | 2025-04-25 |
| Phase | NA |
What the finished NCT06612788 record still lists
NCT06612788 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which Exablate Model 4000 Type 2.0/2.1 is the first listed.
NCT06612788 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06612788 about?
NCT06612788 is a clinical study titled "Exablate for LIFU Neuromodulation in Patients With Opioid Use Disorder (OUD)". The purpose of this clinical trial is to investigate Low Intensity Focused Ultrasound (LIFU) using the Exablate® Model 4000 Type 2.0/2.1 as an adjunctive neuromodulatory treatment for OUD (Opioid Use Disorder) by assessing its safety and tolerability in subjects with OUD.
What is the current status of trial NCT06612788?
This trial is currently completed. It is a NA study. The enrollment target is 5 participants. The study started on 2023-09-19. Estimated completion is 2025-04-25.
What interventions are being tested in trial NCT06612788?
The interventions under investigation include: Exablate Model 4000 Type 2.0/2.1 (DEVICE).
Who is sponsoring clinical trial NCT06612788?
This trial is sponsored by West Virginia University, which has 122 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06612788's enrollment target sits among peer trials
5 1988th of 2000 higher than 5 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI